Care To Live & Deep Capture in a Twitter Over Death of 60,000
29 June 2009 by Mark Mitchell
In the latest chapter of this drama, CNBC's Jim Cramer makes "a mistake" -- again! -- while yet another of his hedge fund friends bets big against Dendreon, a company with a promising treatment for prostate cancer.
* * * * *
To set the record straight I found parts of the video misleading so I asked a friend of mine to comment on the video. Here is what he said.
The video is ok by and large but it is very inaccurate to say that Provenge "does not reduce PSA" or "does not stop the disease from showing up in different places". Neither of these assertions were proven in the trials.
One subtle point about statistical conclusions that lay people always miss is that a trial like IMPACT is designed to prove a hypothesis, not its opposite. That is, failing to prove a hypothesis DOES NOT mean that the same hypothesis is false!
First, despite P-11, PSA was not an endpoint in the relevant trials D9901, D9902a and IMPACT, there was not much to say about whether or not PSA was reduced.
Second, TTP did not achieve statistical significance in the same trials. Therefore, all that we can say here is that there are two possibilities: (1) the disease continues to spread or (2) the methodology used to measure progression was not accurate enough to detect a difference.
However, when the video says that the disease continues to spread, it would mean that (1) was proven. That is far from the truth!
It is well-known that bone scans are hard to read so that different specialists might come up with different assessments. Then, with check-ups weeks or months apart, much noise is introduced into the timing of progression detection. All this points to a weakness in the measurement methodology rather than the disease progression itself.
It is my belief that if progression could be defined more definitely and measured more accurately, we should see Provenge slowing progression too. Otherwise, it makes little sense that patients could survive while the disease continues to spread.
* * * * *
Click link for chapter 1: http://www.deepcapture.com/michael-milken-60000-deaths-and-the-story-of-dendreon-chapter-1-of-15/
Star Reporter Mark Mitchell of DeepCapture.com has just completed 15 Chapters on the Immunotherapy Provenge Debacle and will be releasing them on Deep Capture, one by one. If you are not familiar with the Provenge story, I urge you all to jump down the rabbit hole, for a hare raising view into the corrupt world of Wall Street, Medical Science, the Food and Drug Administration, and the corrupt system that is in place to ensure that they are NOT protecting the health and welfare of the human race. It is a story of the unnecessary death of tens of thousands of men prematurely, while the United States Government flitters away our loved ones lives.
The silence coming out of the FDA is deafening. These men have been waiting for over 2 years to access Provenge, and now they will wait another year. I so hope they can hang on. Ted Girgus, a spokesperson for CareToLive who is afflicted with late stage prostate cancer, has never been able to receive Provenge. As his condition deteriorates, our hearts break, not only for his sickness, but for the sickness in our Government which held hearings for steroids, which no baseball players have died from, yet refused to hold hearings on the corruption at the FDA that occurred with Provenge, despite several Congressman writing a letter for them to do so.
18 June 2009 by Patrick Byrne
For some months Mark Mitchell has been working on his next piece. It has grown into something massive, about the length of The Story of Deep Capture. It concerns Dendreon. I read it for the first time a few days ago. It is semi-infuriating. Deep Capture is going to serialize it. The first piece will [...]
* * * * *
Our Attorney Kerry Donahue filed Plaintiff’s Reply to Defendant’s Memorandum in Opposition Plaintiff’s Motion for Leave to Conduct Discovery Under Civil Rule 56(f)
You can read the response here >> Response for Discovery
See Exhibit A >> exhibit-a-061609.pdf
See Exhibit B >> exhibit-b-061609.pdf
See Exhibit C >> exhibitc.pdf